InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
57,957.54
(
-3.67%
)
Post# of 216
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

TREND1

Send PM Follow Ignore
Followers 416
Posts 52354
Boards Moderated 13
Alias Born 12/16/2001

TREND1

Member Level

Re: None

Thursday, 03/30/2017 1:31:43 PM

Thursday, March 30, 2017 1:31:43 PM

Post# of 216
MannKind Corp.: Bleeding Out And On Its Deathbed

Stephen Fortin

•The non-inferiority of Afrezza to traditional insulin regimens in questionable.

•MNKD has been ineffective in marketing to physicians and the diabetic population alike.

•Script counts are declining, but MNKD needs an 85-fold increase in scripts just to break even.

•Further dilution is coming, and investors should steer clear of the stock.


https://seekingalpha.com/article/4059186-mannkind-corp-bleeding-deathbed?app=1&auth_param=1vat:1cdqf89:05aa6a00d7b88e6106b01c111f6c0bc9&uprof=51

MAIN BOARD http://investorshub.advfn.com/TRADING-3X-TNA-TQQQ-SPXL-RUS-2000-FUTURES-12981/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up